Together, these data show that cervical cancer cells bearing the PIK3CA-E545K mutation have activated PI3K signaling and resistance to cisplatin that can be overcome by inhibition of PI3K with GDC-0941. This evidence concerns the gene PIK3CB and cervical cancer.